CRL vs HUM: fair value comparison
Charles River Laboratories International, Inc. and Humana Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, HUM currently sits closer to the top of our ranking by discount to fair value.
| CRL | HUM | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $301.79 | $431.87 |
| 12-month range | $149.93–$310.77 | $163.67–$433.50 |
| Rank by discount to fair value | #108 of 108 Healthcare | #90 of 108 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CRL fair value analysis · HUM fair value analysis